A Phase I-II Clinical Trial of Pegylated Liposomal Doxorubicin (Doxil(R)) in Combination With BIBF 1120 in Patients With Ovarian Cancer: Hoosier Oncology Group GYN10-149.
Phase of Trial: Phase I
Latest Information Update: 10 Aug 2016
At a glance
- Drugs Nintedanib (Primary) ; Doxorubicin liposomal
- Indications Ovarian cancer
- Focus Adverse reactions; Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 20 Aug 2014 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
- 14 Mar 2014 Trial status changed from recruiting to suspended as reported by ClinicalTrials.gov.